Biotech-focused feature examining strategic pipeline development for rare-disease therapies, emphasizing translational progress and partnership-driven growth. Inviting for industry-minded readers.
Key Takeaways
- Elixirgen granted Nippon Shinyaku an option to commercialize its full-length dystrophin mRNA therapy
- Early Phase 1/2 data showed sustained telomere elongation and neutrophil increases in two patients
- EXG-34217 received FDA Orphan Drug, RMAT, and Rare Pediatric Disease designations